NCT04483440View on ClinicalTrials.gov

Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

May 26, 2027

Study Completion Date

August 31, 2027

Conditions
Choroideremia
Interventions
BIOLOGICAL

4D-110

4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.

Trial Locations (2)

75251

Retina Foundation of the Southwest, Dallas

84132

Moran Eye Center, University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
lead

4D Molecular Therapeutics

INDUSTRY